Arcus Biosciences annual total debt
2020
2021
2022
2023
2024
2025
Arcus Biosciences Total Debt Growth & History (RCUS)
Arcus Biosciences's total debt was $198.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $198.0M | $39.0M | +24.53% |
| 2024 | 2024-12-31 | $159.0M | $38.0M | +31.40% |
| 2023 | 2023-12-31 | $121.0M | −$5.0M | −3.97% |
| 2022 | 2022-12-31 | $126.0M | $12.4M | +10.96% |
| 2021 | 2021-12-31 | $113.6M | $95.4M | +527.03% |
| 2020 | 2020-12-31 | $18.1M | — | — |
Arcus Biosciences quarterly total debt
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $114.0M | $5.0M | +4.59% |
| Q1 2026 | 2026-03-31 | $113.0M | $53.0M | +88.33% |
| Q4 2025 | 2025-12-31 | $198.0M | $39.0M | +24.53% |
| Q3 2025 | 2025-09-30 | $111.0M | $53.0M | +91.38% |
| Q2 2025 | 2025-06-30 | $109.0M | $98.0M | +890.91% |
| Q1 2025 | 2025-03-31 | $60.0M | $49.0M | +445.45% |
| Q4 2024 | 2024-12-31 | $159.0M | $38.0M | +31.40% |
| Q3 2024 | 2024-09-30 | $58.0M | $49.0M | +544.44% |
| Q2 2024 | 2024-06-30 | $11.0M | — | — |
| Q1 2024 | 2024-03-31 | $11.0M | — | — |
| Q4 2023 | 2023-12-31 | $121.0M | −$5.0M | −3.97% |
| Q3 2023 | 2023-09-30 | $9.0M | −$110.2M | −92.45% |
| Q4 2022 | 2022-12-31 | $126.0M | $12.4M | +10.96% |
| Q3 2022 | 2022-09-30 | $119.2M | $67.5M | +130.55% |
| Q2 2022 | 2022-06-30 | $121.3M | $69.1M | +132.46% |
| Q1 2022 | 2022-03-31 | $114.8M | $100.1M | +680.74% |
| Q4 2021 | 2021-12-31 | $113.6M | $95.4M | +527.03% |
| Q3 2021 | 2021-09-30 | $51.7M | — | — |
| Q2 2021 | 2021-06-30 | $52.2M | — | — |
| Q1 2021 | 2021-03-31 | $14.7M | — | — |
| Q4 2020 | 2020-12-31 | $18.1M | — | — |
Arcus Biosciences total debt trends
Over the last five fiscal years, Arcus Biosciences's total debt increased from $18.1M to $198.0M, a change of $179.9M. The latest reported quarter, Q2 2026, shows $114.0M.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
